Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.

FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease

Biogen Inc. BIIB, -1.85% received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker's proposed amyotrophic lateral sclerosis, or ALS, treatment did not show it was effective. On Wednesday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 5-3 with one abstention that the study did not “provide convincing evidence of the effectiveness of toferson,” the name of the treatment for the proposed indication.

Biogen ALS drug considered not effective by FDA advisory panel

FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.

FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease

Incyte

Inspire Medical Systems Inc

Harmony Biosciences Holdings

Eli Lilly

McKesson

Merck

Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

Ionis Pharma

It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.

Wall Street predicts approval for another ALS drug

The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a "clinical benefit" on a rare and aggressive form of the disease.

FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease

Biogen's blockbuster drugs are losing exclusivity -- and that's weighing on earnings. The company now is counting on its latest Alzheimer's drug to turn things around.

Should You Buy Biogen Before a Big July Decision?

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the EMA's refusal to evaluate a generic version of TECFIDERA® (dimethyl fumarate) because of TECFIDERA's regulatory data and marketing protection. With this favorable decision, Biogen believes that TECFIDERA is entitled to regulatory marketing protection in the European Union until at least February 4, 2024. Biogen will seek to enforce this protection and continue to enforce its EP 2 653 873 patent related to TECFIDERA, which expires in 2028.

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

Biogen recently won U.S. approval for an important Alzheimer's disease therapy. However, this medicine still faces some concerning headwinds in the market.

1 Reason to Buy Biogen Stock, and 1 Reason to Sell

Eisai Co. Ltd. JP:4523 said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer's disease treatment it developed with Biogen Inc. BIIB that received an accelerated approval in January.

Veterans Health to cover Eisai, Biogen's new Alzheimer's drug

CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer.

Biogen Appoints Chuck Triano as Head of Investor Relations

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company's 2023 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 14, 2023. Ms. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting.

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

SAGE Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

Adobe

Amazon

Blackrock Inc

Comcast

CME Group

Compass Minerals

Salesforce

Cisco Systems

Dominion Energy

Disney

Domino's Pizza

Ecolab

Equifax

Emerson Electric

Etsy

Gilead Sciences

Alphabet

Guidewire Software

Honeywell

Intercontinental Exchange

International Flavors & Fragrances

Intuit

Johnson & Johnson

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map

Biogen Q4 revenue was down 7% y/y. Zuranolone is a breakthrough depression therapy with an August 5, 2023, PDUFA date.

Biogen Should Resume Strong Growth With Zuranolone Approval

Biogen Inc. (NASDAQ:BIIB ) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ET Company Participants Christopher Viehbacher - Chief Executive Officer Conference Call Participants Philip Nadeau - Cowen & Company Philip Nadeau Welcome to the TD Cowen 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen.

Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

AbbVie

Do you have these three biotech stocks on your watchlist right now?

3 Biotech Stocks To Watch Ahead Of March 2023

Amgen

VanEck Vectors Biotech ETF

Horizon Pharma

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

The latest earnings from some of the big biotech players came in at mixed this reporting season.

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

Biogen Inc (NASDAQ:BIIB) shares fell Wednesday after the company reported declining fourth-quarter sales and revealed that it expects that trend to continue in 2023.  The company expects sales to decline by mid-single digit percentages in 2023 after they fell nearly 7% to $2.54 billion in the fourth quarter.

News for Biogen Stock (BIIB)